ARTICLE | Finance
Versant seizes the RNA moment
Why Versant seeded and launched RNA epigenetics play Gotham with $54M
October 12, 2018 9:45 PM UTC
As the RNA space continues to heat up, Versant Ventures opted out of companies looking to modify RNA directly, and instead seeded and launched RNA epigenetics company Gotham Therapeutics.
Versant co-led Gotham’s $54 million series A round, announced on Oct. 10, with Forbion Capital Partners and SR One. Celgene Corp. (NASDAQ:CELG) and Alexandria Venture Investments also participated. ...